Robert W. Baird set a $95.00 price objective on Henry Schein, Inc. (NASDAQ:HSIC) in a research report released on Thursday morning. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus reissued a hold rating and set a $89.00 target price on shares of Henry Schein in a research report on Thursday. Jefferies Group LLC reissued a hold rating and set a $88.50 target price on shares of Henry Schein in a research report on Friday, July 21st. Piper Jaffray Companies raised shares of Henry Schein from a neutral rating to an overweight rating in a research report on Friday, September 15th. Royal Bank Of Canada started coverage on shares of Henry Schein in a research report on Tuesday, September 19th. They set a sector perform rating and a $91.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Henry Schein from a buy rating to a hold rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $92.86.

Shares of Henry Schein (NASDAQ HSIC) traded up 1.73% during midday trading on Thursday, reaching $84.53. 1,054,733 shares of the company’s stock were exchanged. Henry Schein has a 12-month low of $73.11 and a 12-month high of $93.50. The company has a market cap of $13.37 billion, a price-to-earnings ratio of 24.70 and a beta of 1.08. The stock’s 50 day moving average price is $82.53 and its 200 day moving average price is $87.26.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 8th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a net margin of 4.74% and a return on equity of 19.10%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 EPS. Equities analysts anticipate that Henry Schein will post $3.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/henry-schein-inc-hsic-given-a-95-00-price-target-at-robert-w-baird/1644267.html.

Henry Schein announced that its board has approved a share repurchase program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 6.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

In related news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.19% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in HSIC. YorkBridge Wealth Partners LLC boosted its stake in Henry Schein by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after purchasing an additional 28 shares in the last quarter. Sun Life Financial INC boosted its stake in Henry Schein by 8,185.7% in the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after purchasing an additional 573 shares in the last quarter. Lee Financial Co acquired a new stake in Henry Schein in the 2nd quarter worth approximately $161,000. Acrospire Investment Management LLC boosted its stake in Henry Schein by 150.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock worth $183,000 after purchasing an additional 600 shares in the last quarter. Finally, HM Payson & Co. acquired a new stake in Henry Schein in the 2nd quarter worth approximately $204,000. Institutional investors own 44.74% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.